Intellia Therapeutics (NTLA) Enterprise Value (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Enterprise Value for 11 consecutive years, with -$449.9 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 25.21% to -$449.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$449.9 million through Dec 2025, up 25.21% year-over-year, with the annual reading at -$449.9 million for FY2025, 25.21% up from the prior year.
- Enterprise Value for Q4 2025 was -$449.9 million at Intellia Therapeutics, up from -$511.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$449.9 million in Q4 2025, with the low at -$1.2 billion in Q4 2022.
- Average Enterprise Value over 5 years is -$734.4 million, with a median of -$771.0 million recorded in 2021.
- The sharpest move saw Enterprise Value crashed 133.38% in 2021, then surged 36.34% in 2025.
- Over 5 years, Enterprise Value stood at -$750.8 million in 2021, then plummeted by 58.85% to -$1.2 billion in 2022, then grew by 23.51% to -$912.2 million in 2023, then skyrocketed by 34.06% to -$601.5 million in 2024, then increased by 25.21% to -$449.9 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$449.9 million, -$511.0 million, and -$459.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.